Payment overview · 2025
General Payments
$660.94
30 reported records · 15 companies
Healthcare provider profile · identity verified
Abbas H Jafri, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRING, TX · NPI 1891798161
Verified facts
What the public records show
CMS Open Payments records show Abbas H Jafri, MD received $660.94 in general payments during 2025 across 30 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 621 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $145.13 | 22.0% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $102.84 | 15.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.49 | 11.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.56 | 8.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.87 | 6.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.66 | 6.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $35.95 | 5.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.44 | 4.6% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $26.47 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.15 | 3.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.07 | 3.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.16 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.03 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.12 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.00 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $642.78 | 29 |
| Education | $18.16 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $145.13 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $102.84 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $35.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.44 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
621 | 95 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 996 | 285 |
| Gabapentin | Gabapentin | 678 | 168 |
| Eliquis | Apixaban | 621 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 515 | 169 |
| Furosemide | Furosemide | 499 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 377 | 107 |
| Metformin Hcl | Metformin Hcl | 344 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 337 | 93 |
| Lisinopril | Lisinopril | 333 | 116 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 76 |
| Omeprazole | Omeprazole | 292 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 65 |
| Potassium Chloride | Potassium Chloride | 264 | 75 |
| Carvedilol | Carvedilol | 261 | 72 |
| Losartan Potassium | Losartan Potassium | 258 | 100 |
| Mirtazapine | Mirtazapine | 241 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 84 |
| Donepezil Hcl | Donepezil Hcl | 227 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 85 |
| Tramadol Hcl | Tramadol Hcl | 214 | 69 |
| Sertraline Hcl | Sertraline Hcl | 211 | 59 |
| Trazodone Hcl | Trazodone Hcl | 208 | 67 |
| Montelukast Sodium | Montelukast Sodium | 180 | 64 |
| Levetiracetam | Levetiracetam | 178 | 35 |
| Memantine Hcl | Memantine Hcl | 164 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 65 |
| Amiodarone Hcl | Amiodarone Hcl | 157 | 40 |
| Pregabalin | Pregabalin | 145 | 30 |
| Alprazolam | Alprazolam | 141 | 37 |
| Xarelto | Rivaroxaban | 135 | 32 |
| Buspirone Hcl | Buspirone Hcl | 131 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 45 |
| Clonazepam | Clonazepam | 116 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 106 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 105 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 38 |
| Ezetimibe | Ezetimibe | 100 | 28 |
| Farxiga | Dapagliflozin Propanediol | 99 | 19 |
| Simvastatin | Simvastatin | 98 | 32 |
| Ozempic | Semaglutide | 97 | 26 |
| Divalproex Sodium | Divalproex Sodium | 93 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 54 |
| Sucralfate | Sucralfate | 91 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 25 |
| Allopurinol | Allopurinol | 85 | 33 |
| Famotidine | Famotidine | 84 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 83 | 26 |
| Spironolactone | Spironolactone | 83 | 26 |
| Azithromycin | Azithromycin | 81 | 58 |
| Meloxicam | Meloxicam | 79 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 25 |
| Glipizide | Glipizide | 76 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 30 |
| Lorazepam | Lorazepam | 74 | 25 |
| Methocarbamol | Methocarbamol | 72 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 26 |
| Januvia | Sitagliptin Phosphate | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 16 |
| Jardiance | Empagliflozin | 68 | 14 |
| Prednisone | Prednisone | 68 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 26 |
| Alendronate Sodium | Alendronate Sodium | 67 | 21 |
| Nifedipine Er | Nifedipine | 66 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 19 |
| Latanoprost | Latanoprost | 61 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Celecoxib | Celecoxib | 55 | 16 |
| Bupropion Xl | Bupropion Hcl | 54 | 17 |
| Lactulose | Lactulose | 53 | 24 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 26 |
| Finasteride | Finasteride | 52 | 22 |
| Methylprednisolone | Methylprednisolone | 52 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 34 |
| Glimepiride | Glimepiride | 50 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 11 |
| Baclofen | Baclofen | 46 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 45 | 19 |
| Metformin Hcl Er | Metformin Hcl | 45 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Temazepam | Temazepam | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 16 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 19 |
| Midodrine Hcl | Midodrine Hcl | 40 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 16 |
| Risperidone | Risperidone | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Atenolol | Atenolol | 38 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Valsartan | Valsartan | 34 | 13 |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Cephalexin | Cephalexin | 32 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 18 |
| Nystatin | Nystatin | 30 | 19 |
| Budesonide | Budesonide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Digoxin | Digoxin | 27 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Zonisamide | Zonisamide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $660.94 · 30 records | Teva Pharmaceuticals USA, Inc. | APTIMA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, GEMTESA, INCEPTIV, JARDIANCE, MOUNJARO, NUPLAZID, Ozempic, PAXLOVID, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, Veozah, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error